Skip to content
2000
Volume 7, Issue 6
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Multiple myeloma (MM) is a plasma cell malignancy characterized by the high capacity to induce osteolytic bone lesions. Bone destruction in MM mainly depends on the increase of osteoclast formation and activity that occurs in close contact with myeloma cells infiltration. The histomorphometric studies, performed in MM patients, have demonstrated that MM patients with high plasma cell infiltrate are also characterized by a lower number of osteoblasts and a decreased bone formation that contributes, to the development of bone lesion. In the last years the progress in acknowledge of the pathophysiology of MM-induced osteolysis leaded to identify new therapeutics targets in MM bone disease and developed new drugs in the treatment of patients with skeletal involvement

Loading

Article metrics loading...

/content/journals/cpb/10.2174/138920106779116955
2006-12-01
2025-07-26
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/138920106779116955
Loading

  • Article Type:
    Research Article
Keyword(s): drugs; Multiple Myeloma; osteoblast; osteoclast; RANKL
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test